Results 241 to 250 of about 87,437 (368)

Measurable residual disease‐guided therapy in acute myeloid leukaemia: Practical insights

British Journal of Haematology, Volume 207, Issue 4, Page 1192-1212, October 2025.
Summary Measurable residual disease (MRD) is a prognostic marker in patients with acute myeloid leukaemia (AML). This review examines the role of MRD assessment in guiding treatment strategies. We evaluate key questions, such as the prognostic power of MRD in specific genetic subgroups of AML, the optimal pre‐emptive approach for MRD persistence or ...
Boaz Nachmias, Arnon Haran, Meira Yisraeli Salman, Eytan M. Stein   +3 more
wiley   +1 more source

Sex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis. [PDF]

J Clin Med
Darphin X, Blattner J, Hoffmann M, Gobat K, Kronig MN, Pabst T, Özdemir BC.   +6 more
europepmc   +1 more source

Cost‐effectiveness of imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia [PDF]

, 2004
Shelby D. Reed, Kevin J. Anstrom, J Ludmer, G. Alastair Glendenning, Kevin A. Schulman   +4 more
openalex   +1 more source

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG‐MESRAT study

British Journal of Haematology, Volume 207, Issue 4, Page 1271-1278, October 2025.
Summary EWOG‐MESRAT (European Working Group—Methylation Signatures and Response to Azacitidine Therapy; DRKS00007185) is an investigator‐initiated trial that studied EPIC array‐based DNA methylation patterns and next generation sequencing (NGS)‐based variant allele frequencies (VAFs) of driver mutations in peripheral blood (PB) and bone marrow (BM) of ...
Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, Dirk Lebrecht, Thomas Klingebiel, Franco Locatelli, Karsten Nysom, Claudia Rossig, Jan Starý, Marco Zecca, Meera Patturajan, Miriam Erlacher, Brigitte Strahm, Charlotte M. Niemeyer, Daniel B. Lipka, Christian Flotho   +15 more
wiley   +1 more source

Analysis of remobilization efficiency of etoposide combined with cytarabine and pegfilgrastim, with or without plerixafor, for multiple myeloma recurrence following autologous hematopoietic stem cell transplantation. [PDF]

Clin Exp Med
Zhou Y, Qian H, Zheng J, Lu Y, Ye P.
europepmc   +1 more source

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

Clinical Cancer Research, 2016
Xiaojia Niu, Jianyun Zhao, Jun Ma, C. Xie, Holly Edwards, Guan Wang, J. T. Caldwell, Shengyan Xiang, X. Zhang, R. Chu, Z. Wang, Hai Lin, J. Taub, J. Taub, Y. Ge   +14 more
semanticscholar   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia. [PDF]

Cancer Med
Cai Y, Rui J, Ding Z, Xie J, Jin Z, Xiao J, Xu Y.   +6 more
europepmc   +1 more source

Nonbacterial Thrombotic Endocarditis [PDF]

, 2020
Atallah, Rami, Chamoun, Kamal, Nehme, Fredy, Ojile, Nicholas, Parker, Nathaniel, Vindhyal, Mohinder   +5 more
core   +2 more sources

Magnetic Resonance Imaging Findings in a Case of Cytarabine-Induced Myelopathy

, 2002
Paul M. Sherman, Clifford J. Belden, Douglas A. Nelson   +2 more
openalex   +1 more source

Granulocyte‐macrophage colony‐stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial [PDF]

, 2004
Christina Löfgren, Christer Paul, Maria Åström, Robert Hast, M. Hedenius, R. Lerner, Jan Liliemark, Inga‐Lena Nilsson, Stig Rödjer, Bengt Simonsson, Dick Stockelberg, Ulf Tidefelt, Magnus Björkholm   +12 more
openalex   +1 more source